{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:29:48Z","timestamp":1753439388332,"version":"3.37.3"},"reference-count":19,"publisher":"Informa UK Limited","issue":"7","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82073936"],"award-info":[{"award-number":["82073936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Bioanalysis"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.4155\/bio-2021-0281","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T09:37:51Z","timestamp":1646905071000},"page":"421-439","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Regulated Bioanalysis of Liposomal Amphotericin B to Support Pharmacokinetic Studies of Liposomal Drugs"],"prefix":"10.1080","volume":"14","author":[{"given":"Xueyuan","family":"Zhang","sequence":"first","affiliation":[{"name":"CSPC Zhongqi Pharmaceutical Technology (SJZ) Co., Ltd., Shijiazhuang, Hebei Province, China"},{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhuan","family":"Ji","sequence":"additional","affiliation":[{"name":"Chongqing Denali Medpharma Co., Ltd., Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinzhi","family":"Liu","sequence":"additional","affiliation":[{"name":"Chongqing Denali Medpharma Co., Ltd., Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Liu","sequence":"additional","affiliation":[{"name":"Chongqing Denali Medpharma Co., Ltd., Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlei","family":"Li","sequence":"additional","affiliation":[{"name":"CSPC Zhongqi Pharmaceutical Technology (SJZ) Co., Ltd., Shijiazhuang, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laixin","family":"Wang","sequence":"additional","affiliation":[{"name":"Chongqing Denali Medpharma Co., Ltd., Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Meng","sequence":"additional","affiliation":[{"name":"Chongqing Denali Medpharma Co., Ltd., Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-8028","authenticated-orcid":false,"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0538-7"},{"key":"e_1_3_6_4_1","unstructured":"US Food and Drug Administration. Liposome drug products chemistry manufacturing and controls; human pharmacokinetics and bioavailability; and labeling documentation guidance for industry (2018). https:\/\/www.fda.gov\/media\/70837\/download"},{"key":"e_1_3_6_5_1","unstructured":"European Medicines Agency. Committee for Human Medicinal Products (CHMP) reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. (2013). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-data-requirements-intravenous-liposomal-products-developed-reference-innovator_en.pdf"},{"key":"e_1_3_6_6_1","unstructured":"US Food and Drug Administration. Draft guidance on amphotericin B (2020). www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_050740.pdf"},{"key":"e_1_3_6_7_1","unstructured":"US Food and Drug Administration. Draft guidance on doxorubicin hydrochloride (NDA 050718 RV 09-2018)."},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200106000-00015"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00292-4"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.11.036"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.06.014"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2017.11.020"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113388"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.03.034"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2018.08.003"},{"key":"e_1_3_6_16_1","unstructured":"Chinese Pharmacopeia 9012 Guidance for Quantitative Bioanalytical Method Validation Guidelines (2015)."},{"key":"e_1_3_6_17_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. US Food and Drug Administration Guidance for industry: bioanalytical method validation (2018). www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry"},{"key":"e_1_3_6_18_1","unstructured":"European Medicines Agency. EMA guideline on bioanalytical method validation (2012). www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf"},{"key":"e_1_3_6_19_1","unstructured":"European Medicines Agency. Draft ICH harmonised guideline M10 on bioanalytical method validation (2019). www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-ich-guideline-m10-bioanalytical-method-validation-step-2b_en.pdf"},{"issue":"12","key":"e_1_3_6_20_1","first-page":"3","article-title":"Liposomal formulation in clinical use: an updated review","volume":"9","author":"Bulbake U","year":"2017","unstructured":"Bulbake U , DoppalapudiS, KommineniN, KhanW. Liposomal formulation in clinical use: an updated review. Pharmaceutics9(12), 3\u201333 (2017).","journal-title":"Pharmaceutics"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.834-840.2002"}],"container-title":["Bioanalysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/bio-2021-0281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T17:00:23Z","timestamp":1715965223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/bio-2021-0281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.4155\/bio-2021-0281"],"URL":"https:\/\/doi.org\/10.4155\/bio-2021-0281","relation":{},"ISSN":["1757-6180","1757-6199"],"issn-type":[{"type":"print","value":"1757-6180"},{"type":"electronic","value":"1757-6199"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}